Diagnostic methods are not efficient and 9.6 million people die from blood cancer annually. That’s why Mantiscope has developed a blood analysis solution through artificial intelligence with the goal of preventing 70% of blood cancer deaths worldwide, especially in rural areas.
Currently, it is in a pre-industrialization state after the technology has been validated with blood samples from more than 4.500 patients in various hospitals in Turkey and is undergoing pilot tests at the Hospital Clínic de Barcelona.
- Pilots: 5 – Hacettepe University, Tobb Etu, Afyon, Hospital Clinic (Barcelona), Tuseb.
- Maturity: Pre-industrialization
- Capital raised: 0€
- Company Valuation: 2,5 M€
- Open Round: Yes
Mantiscope is an innovative service combining cloud-based software and hardware to revolutionize blood sample analysis using artificial intelligence and image processing technologies. This advanced system aims to transform traditional diagnostic methods for blood-related conditions such as blood cancer, anemia, thalassemia, and malaria, which are often costly and time-consuming.
The main value proposition is to eliminate the disparity in diagnostic services by equipping rural hospitals with Mantiscope, ensuring that timely and accurate diagnoses are accessible to all, to bridge the gap in healthcare access and improve patient outcomes.
- Sector: Health tech
- Country: Turkey
- Nº of workers: 5
Watch this video to know more:
